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A B S T R A C T
Honey is a food known for its medical properties. In this work, we have studied the impact of different types of
honey on insulin signalling pathway. We found that honey extracts inhibit the enzyme PTP1B, one of the main
negative regulators of insulin receptor signalling. HPLC-MS analysis allowed us to confirm the presence of
several natural PTP1B inhibitors in the honey extracts analysed. Statistical analysis methods show a correlation
between specific 1H-NMR resonance frequencies/HPLC peaks and the inhibitory power of the samples. This
finding will allow the prediction of the biological properties of honey samples applying relative simple analytical
methods. Finally, we demonstrated that the treatment of HepG2 cells with honey extracts enhances the ex-
pression of insulin receptor, and stimulates glucose uptake. For the first time, our results demonstrate that
bioactive components of honey could improve glycaemic control by both inhibiting PTP1B and stimulating the
expression of insulin receptor in liver cells.
1. Introduction
Based on data of the last WHO report, to date more than 400 million
of people worldwide suffer of diabetes. Type 2 diabetes, the most
common diabetes form, is a chronic disease characterized by hy-
perglycaemia resulting from alterations of physiological mechanisms
that contribute to maintain glucose homeostasis. Diabetic patients have
to assume daily oral anti-hyperglycaemic drugs, or resort to insulin
injections to maintain glycaemia under physiological range.
Unfortunately, regardless of the therapeutic approach used, most dia-
betic people see their health status worsen over time, because of da-
mages on the cardiovascular and nervous apparatus. Only in the 2012,
more than 1.5 million of people affected by diabetes aged between 20
and 79 years old, died from complications related to this pathology [1].
It is established that sedentary lifestyle, hyper-caloric diets, and
obesity are the main non-genetic risk factors that contribute to the onset
of type 2 diabetes in the people aged 15–69 years. Thus, corrective
actions aimed to modify the eating habits of people, to promote
physical activity, are considered important measures to prevent the
onset of type 2 diabetes in all countries [2].
Honey, the product of honeybee, is the most ancient natural
sweetener known to mankind. It contains sugars (monosaccharides,
disaccharides and oligosaccharides), vitamins, amino acids, proteins,
mineral salts, trace elements, and many natural compounds such as
flavonoids, phenolic and organic acids. These compounds are re-
sponsible for medical properties of honey, such as antibacterial, anti-
inflammatory, antioxidant, antiproliferative, anticancer and antimeta-
static activity [3,4]. Although it could seem counter-intuitive, several
studies published in the last decade demonstrated that a moderate
consumption of honey contributes to regulate glycaemia, and to prevent
pathological complications in diabetic people [5–12]. Despite all the
evidences produced to date, the molecular mechanisms of honey's anti-
hyperglycemic activity still need to be clarified.
Recent studies demonstrated that several natural compounds ex-
tracted from fruits and vegetables, inhibit PTP1B, showing IC50 values
in the μM range [13–15]. PTP1B is one of the most important negative
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regulators of insulin signalling pathway and it is universally recognized
as one of the most promising pharmacological target for the treatment
of type 2 diabetes [16]. Since honey contains several phenolic com-
pounds, we decided to investigate whether honey solutions were able to
inhibit PTP1B, thereby enhancing insulin signalling pathway. To this
aim, we selected twenty Tuscany honey samples belonging to four
different floral varieties, such as honeydew, chestnut, wildflowers and
acacia, representing some of the most abundant honey types produced
in this region. Starting from each sample, we obtained hydroalcoholic
solutions that we analysed for their ability to inhibit PTP1B. Moreover,
we determined the IC50 values of active extracts and we studied the
action mechanism of the most active ones. At the same time, HPLC-DAD
and 1H-NMR technologies were used to characterize these solutions,
while LC–MS technology was used to identify the molecules present in
the active extracts. Furthermore, statistical tools, namely PCA and LDA,
were applied for correlating biological and chemical results and for
creating a predictive model on honey inhibitory activity. Finally, the
biological activity of honey extracts was confirmed ex vivo, by using
human HepG2 cells.
2. Materials and methods
2.1. Materials
General reagents and culture media were purchased from Sigma-
Aldrich. All organic solvents used for HPLC analysis were high-perfor-
mance liquid chromatography grade and were purchased from Sigma-
Aldrich. Human insulin was from Eli Lilly and Co. [3H] D-glucose was
purchased from Perkin-Elmer. Antibodies: anti p-IRβ (Y 1162–1163),
anti IRβ, and p-nitrophenyl phosphate were purchased from Santa Cruz
Biotechnology Inc. HepG2 cells were obtained from the European
Collection of Animal Cell Cultures, Salisbury, UK.
2.2. Methods
2.2.1. Preparation of the honey extracts
For biological assay, honey hydroalcoholic solutions were prepared
by dissolving 5 g of honey in 25mL of ethanol 80% v/v. Samples were
left at room temperature under shaking for two hours, and then cen-
trifuged to remove the insoluble residue. Supernatant was collected and
stored at 4 °C. The extracts were named with the following symbols: H1-
5, honeydew; W1-5, wildflowers; C1-C5, chestnut; A1-5, acacia.
Solutions for 1H-NMR spectra were prepared by dissolving about
100mg of honey in 0.5mL of H2O:D2O mixture (90:10). 10 μL of maleic
acid solution (110mg/mL) as internal standard (IS) were added.
Insoluble residue was removed by centrifugation at 11,000 rpm for
2min.
For the HPLC analysis, about 100mg of each honey sample were
solubilised in 1mL of milli-Q water. Honey solubilisation was carried
out by shaking with a vortex for 1min. The obtained solutions were
centrifuged (14,000 rpm, rt, 5 min) to remove the undissolved residue
before the chromatographic analysis. The same samples were used for
the LC-HR-MS analysis.
2.2.2. Enzymatic assay
Enzymatic assays were carried out using recombinant PTP1B en-
zyme and p-nitrophenyl phosphate (p-NPP) as synthetic substrate.
Recombinant PTP1B was prepared as previously described [17]. All
enzymatic assays were carried out in 0.075M β,β-dimethylglutarate
buffer (pH 7.0), containing 0.1mM DTT, 1mM EDTA and 2.5mM p-
NPP. Each assay was started by adding an aliquot of the enzyme, and
was stopped after appropriate time using 2mL of 0.1M KOH. The
amount of the released p-nitrophenolate was determined measuring the
absorbance at 400 nm in a 1 cm pathlength glass cuvette. The value of
extinction coefficient (εmM) of p-nitrophenolate at pH 7.0 was 18. All
assays were carried out in triplicate.
To determine the IC50 value of the different honey samples, several
assays were carried out using a fixed substrate concentration, corre-
sponding to Km of the enzyme, and increasing amounts of honey solu-
tions. The obtained data were normalized respect to a control test, and
fitted using the following equation:
= + +( )ViV Max Min Min0 1 XIC slope50
where Vi/V0 represent the ratio between the enzymatic rate calculated
in presence of each inhibitor concentration, and the enzymatic rate
calculated in absence of inhibitor; “Max” represent the maximum value
of activity, while “Min” the minimum value of activity; “x” represents
the concentration of the inhibitor; IC₅₀ was the concentration of the
inhibitor able to decrease up to 50% the enzymatic activity; finally, the
term “slope”, represents the slope of the curve in the transition zone.
2.2.3. Determination of the mechanism of action of honey extracts
To verify whether the extracts behaved as reversible inhibitors,
aliquots of the enzyme were incubated for 1 h at 37 °C in presence of
saturating concentration of each extract. After this time, an aliquot of
each sample was diluted 400 fold in the assay buffer containing p-NPP
to determine the enzyme’s residual activity. The kinetic parameters, Km
and Vmax, were determined by measuring the initial hydrolysis rates in
the presence of increasing substrate concentrations and by fitting these
data with the Michaelis-Menten equation. All tests were carried out in
triplicate. To determine the value of the inhibition constant (Ki), the
dependence of Km and Vmax from the concentration of honey extract
was studied. Data obtained from enzymatic assays were reported on a
double reciprocal plot, according to Lineweaver-Burk method.
Considering that honey extracts behaved as linear mixed type non-
competitive inhibitors (see Scheme 1 below), the value of inhibition
constant (Ki) was determined using the equations 1 and 2.
Scheme 1. Mixed-type non-competitive inhibition. E, free enzyme; ES en-
zyme-substrate complex; EI, enzyme-inhibitor complex; ESI, enzyme-substrate-
inhibitor complex; Ks, enzyme substrate complex dissociation constant; Ki,
enzyme-inhibitor complex dissociation constant; α > 1. The Ki values were
determined applying equations 1 and 2.
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2.2.4. Determination of total phenolic and flavonoid content
The total phenolic content was determined by the Folin-Ciocalteau
method. The assay was carried out in 96 multiwell plates. Briefly, 20 μL
of ethanolic solution were diluted with 100 μL of Folin-Ciocalteau re-
agent and stored at room temperature for 10min. After this time,
samples were diluted with 80 μL of 7.5% Na2CO3 and stored at room
temperature for 90min. Optical density of samples was measured at
595 nm using a Microplate reader (BioRad). Each test was carried out in
triplicate. A calibration curve was built using 5, 10, 15, 20, 25, 37.5,
and 50 μg/mL solution of gallic acid as external standard.
The total flavonoid content was measured using the colorimetric
assay developed by Zhishen et al. [8]. The honey solution (10 μL) was
mixed with 4 μL of distilled water. At the baseline, 3 μL of NaNO2
(0.5%, w/v) were added. After 5min, 3 μL of AlCl3 (1% w/v) were
added, followed by the addition of 20 μL of NaOH 1M (6min later).
The volume was then increased to 100 μL by the addition of distilled
water. The mixture was vigorously shaken to ensure adequate mixing,
and the absorbance was read at 510 nmA calibration curve was created
using a standard solution of catechin (20, 40, 60, 80, and 100 μg/mL;
R2=0.998). The results were expressed as mg catechin equivalents
(CEQ) per kg of honey.
2.2.5. Color of honey samples
Briefly, 1mL of the honey extract was transferred in a 1 cm path
wavelength grass cuvette before the analysis. The absorbance of the
samples was measured at 450 and 720 nm, and the difference in ab-
sorbance was expressed as mAU.
2.2.6. 1H-NMR analysis
1H-NMR spectra were recorded on a Bruker Avance 400 spectro-
meter (400MHz for 1H-NMR) from Bruker Italia (Milan, Italy), oper-
ating at 298 K using a 5mm probe. 1H-NMR spectra were acquired in
the following conditions: acquisition time, 1.71 s; spectral width,
4790 Hz; recycling delay, 5 s. Water suppression was performed using
the pulse sequence with presaturation “zgpr” (Avance-version 12/01/
11).
The peak heights were normalized based on the height of the signal
at 6.2 ppm of the internal standard (maleic acid).
2.2.7. HPLC analysis
HPLC-DAD analyses were performed by using a HP-1200 L Liquid
Chromatograph provided with a DAD detector all from Agilent
Technologies, (Palo Alto, CA, USA). A 150mm x 3mm i.d., 2.7 μm
Poroshell 120, EC-C18 column equipped with a precolumn of the same
phase was used (Agilent Technologies). Solvents for the mobile phase
were (A) 0.1% formic acid/water and (B) CH3CN; flow rate 0.4 mL/min;
the multi-step linear solvent gradient used was: 0–15min 2–15% B;
15–25min 15–30% B; 25–31min 30–45% B; 31–35min 45–100% B;
35–37min 100% B; 37–43min 100–2% B; the equilibration time after
each analysis was 10min. The wavelengths simultaneously selected
were: 280 nm and 330 nm.
Semi-preparative HPLC analyses were performed using a DIONEX
P680-UVD170U system equipped with a Kinetex C18 column, 5 μm,
100 Å, 250×4.6mm (Phenomenex). Elution was performed at a flow
rate of 0.8 mL/min applying the same gradient used for the analytical
HPLC-DAD; the elution mixture contained acidified water by HCOOH
(solvent A) and 10mM of trifluroacetic acid in acetonitrile (solvent B).
For each analysis, 100 μL of sample were injected and detection was
based on absorbance at 280 and 330 nm.
2.2.8. LC–MS analysis
LC–MS analyses were carried out by using a qTOF mass spectro-
meter Impact II coupled to an UltiMate™ 3000 UHPLC System. 20 μL of
each sample were used for the analysis. Samples were separated by
reverse phase chromatography (RESTEK Ultra C18, 3 μm particle size,
100mm length), using a flow rate of 0.4mL/min using a water/CH3CN
gradient. Briefly, the mobile phases were (A) 0.1% formic acid in water
and (B) CH3CN. The applied multi-step linear solvent gradient was:
0–15min 5–15% B; 15–25min 15–30% B; 25–31min 30–45% B;
31–35min 45–95% B; 35–45min 95% B; 45–50min 95–5% B; the
equilibration time after each analysis was 8min.
Each sample was analysed twice in negative and in positive ion
mode. Metabolites were ionized by ESI and analysed in the mass
spectrometer with the following parameters: ion spray voltage 3000 V
(4500 V for positive ion mode), enplate offset 500 V, dry gas 8 L/min,
drying temperature 220 °C and nebulizing gas pressure 1.8 bar. The
mass spectra were acquired in the m/z range 50–1300 and 20 μL were
injected for each run.
The calibration ions in the pre-run internal calibration were gen-
erated as sodium formiate cluster ions. Theoretical masses of calibra-
tion ions were: 158.964069, 226.951493, 294.938917, 362.926341,
430.913765, 498.901189, 566.888613, 634.876037 and 702.863461 in
positive ion mode, and 112.985627, 180.973051, 248.960475,
316.947899, 384.935323, 452.922747, 520.910170, 588.897594,
656.885018 and 724.872442 in negative ion mode.
The spectra were calibrated using data analysis 4.4 (Bruker,
Bremen, Germany), analysed with profile analysis 2.3 (Bruker, Bremen,
Germany), and matched with an analyte list of 117 compounds iden-
tified from honey samples using the software Metaboscape (Bruker,
Bremen, Germany).
2.2.9. Statistical analysis
Data from 1H-NMR and HPLC were statistically analyzed by PCA
and LDA: the values of frequency and the signal intensity from 1H-NMR
data, and the peak areas from the chromatographic profiles of HPLC
analysis were selected.
PCA was based on 1H-NMR, in which the resonance frequencies
were the variables, and the signal intensities were the corresponding
values. Each variable was defined as a frequency range of 0.5 ppm,
consequently, the related values were the sum of the intensities of the
signals belonging to that ranges.
For the PCA applied to HPLC data, the retention times were the
variables, and the peak areas were the related values. Each variable was
defined as retention time ranges of 1min, therefore the related values
were the sum of the peak areas belonging to these ranges.
Chromatograms were recorded at 240, 280 and 330 nm. LDA was ap-
plied, in both cases, selecting the three principal components derived
by PCA
2.2.10. Ex vivo assay
The activity of the honey extracts was assayed on in cell model
system using HepG2 cell line. Cells seeded in P35 plates (150.000 cells/
dishes) were routinely grown in DMEM medium, containing 10% FBS,
glutamine, streptomycin and penicillin. When the cells reached 70%
confluence, the growth medium was withdrawn and substituted with
starvation medium (DMEM high glucose without FBS). After 20 h, the
cells were incubated with a fresh starvation medium containing 0.02%
of honey extracts (1 μL/mL of extract). These cells were incubated for 4
days with honey extracts; each 24 h, the medium was substituted with
fresh medium containing fresh extracts. Then, the cells were washed
with PBS, and stimulated with 10 nM insulin. Control test were carried
out incubating liver cells with an equal amount of 80% ethanol solu-
tion. Cells were lysed using 150 μL of 1X sample buffer (the solution
contains 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.002%
bromphenol blue and 0,0625M Tris HCl, pH 6.8), scraped, collected in
an eppendorf tube, and boiled for 5min. Fifteen microliters of each
protein extracts were loaded onto 12% SDS-PAGE. After running, pro-
teins were transferred onto PVDF membrane by western blot technique.
Expression levels of insulin receptor and activated form of insulin re-
ceptor were evaluated using specific antibodies (IRβ antibodies and p-
insulin Rβ Antibody (Tyr 1162/1163, respectively). The antibodies
were purchased from Santa Cruz Biotechnology. The obtained values
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were normalized with respect to actin expression level.
2.2.11. Glucose uptake
HepG2 cells (30.000 cells/well) were seeded in 24 well plate. After
24 h cells were starved for 20 h and then incubated in the presence of
starvation medium containing 0.1 mCi of 2-deoxy-D-1,2-[3H]-glucose
(20 Ci/mmol). Cells were incubated at 37 °C for 30min, then washed
with cold PBS and lysed in 0.2M NaOH. Aliquots of the lysates were
counted with a β-scintillation counter, and the data were normalized
against protein concentration.
3. Results
3.1. Determination of total phenolic amount and flavonoids content
A preliminary spectrophotometric analysis showed that honey ex-
tracts strongly differ in term of natural pigments content
(Supplementary Fig. 1A). To estimate the content of phenols and fla-
vonoids in each sample, spectrophotometric tests were carried out. We
found that the chestnut and honeydew extracts were richer in phenols
and flavonoids than wildflowers and acacia honey samples
(Supplementary Fig. 1B, C).
3.2. Evaluation of the inhibitory activity of honey
Enzymatic assays were carried out to evaluate the ability of each
extract to inhibit PTP1B. The obtained results showed that the in-
hibitory power of the extracts differs, depending on the floral origin of
honey. Among all, honeydew and chestnut extracts appeared to be the
most active samples, while wildflower and acacia extracts showed a
weaker inhibitory power (Fig. 1A–E).
To better evaluate the inhibitory power of each honey extract, we
determined the IC50 values (Table 1). Data reported in Table 1 con-
firmed that the honeydew extracts were more effective than chestnut,
and wildflowers samples (the mean IC50 values were 12 μL/mL, 27.8
μL/mL or and 31.7 μL/mL for honeydew, chestnut, and wildflower
extracts, respectively), while the acacia extracts behaved as very weak
inhibitors. Finally, no correlation was found between the IC50 values
and the total phenolic content (R2= 0.09), whereas a weak correlation
was verified between IC50 values and total flavonoid content
(R2= 0.29) (Fig. 1F). These evidences suggest that flavonoids can be
partially responsible for the inhibitory activity of these honey extracts.
3.2.1. Characterization of inhibitory mechanism of honey extracts
Further enzymatic assays were carried out to clarify the action
mechanism of honey extracts. Firstly, we evaluated whether the most
active samples (H4, C2, and W4) behaved as reversible or irreversible
inhibitors. To this scope, aliquots of the enzyme solution were mixed
with honey extracts (10:1 v/v was the enzyme/extract ratio), and then
incubated at 37 °C for 90min. After this time, an aliquot of the solution
was diluted 400 folds in the assay buffer to evaluate the residual ac-
tivity of the enzyme. We observed that, in all cases, the recovery of
enzyme activity after dilution was almost complete (Supplementary
Fig. 2). This finding suggested that honey extracts behaved as PTP1B
reversible inhibitors. Moreover, kinetic analyses carried out by using
different honey extracts showed that all the samples behaved as mixed-
type non-competitive inhibitors towards PTP1B (Fig. 2, Table 2 and
Supplementary Figs. 3–5).
3.3. HPLC analysis
The most active honey samples (H4, W4, and C2 extracts) and the
A1 extract were analyzed by HPLC-DAD and the detectable peaks were
evaluated at 240, 280, 330 and 350 nm (typical wavelengths applied to
detect the phenolic compounds). In the chromatograms of the acacia
extracts, only few peaks were detectable, suggesting the presence of low
amount of potentially bioactive phenolic compounds. Conversely, the
chromatographic profiles obtained from honeydew, chestnut and
wildflowers honey samples, showed a higher number of constituents.
(Supplementary Fig. 6). To identify the active fractions, we repeated the
analysis by testing different samples obtained by using a semi-pre-
parative HPLC-column. One hundred microliters of active samples (H4,
W4, and C2 honey extracts) were injected, and four fractions were
collected (Supplementary Figs. 7–9). All fractions were dried under
vacuum, and then solubilized in 100 μL of 80% ethanol to reestablish
the original concentration of the analytes, as in the whole honey
sample. Finally, all the fractions were assayed to evaluate their in-
hibitory power on PTP1B. Fractions from H4 sample showed a weak
inhibitory activity respect to the whole ethanolic extract (Fig. 3A and
Supplementary Fig. 7). This evidence suggested that the compounds
responsible for the inhibitory activity were lost during the drying of the
sample because were volatile molecules. Conversely, we observed that
the fraction 4 derived from C2 (Fig. 3B and Supplementary Fig. 8) and
the fractions 3 and 4 from W4 sample (Fig. 3C and Supplementary
Fig. 9), showed an inhibitory power comparable to that of the original
extract. Considering the retention time of these bioactive compounds,
eluted with a high organic solvent percentage, we hypothesize they
possess aromatic or aliphatic hydrophobic groups.
3.4. 1H-NMR analysis
Based on the results above, in order to evaluate all the organic
components of the honey samples, the 1H-NMR experiments were car-
ried out on water solutions, in which the whole honey was completely
dissolved.
From the statistical analysis of our results, the activity resulted as-
sociated to molecules of various molecular weights, but having an
aromatic group. In particular, we found that the resonance signals at
frequencies around 8 ppm correlated with the inhibitory activity.
Characteristics of this type suggest the presence of molecules with
aromatic structures coplanar to a carbonyl group as those observed in
several flavonoids classes (e.g. flavone, flavonols).
3.5. Statistical analysis of data
The final goals was to identify honeys able to inhibit PTP1B and to
hypothesize the chemical-physical characteristics of the compounds
responsible for the inhibitory activity.
Based on IC50 values, the honeys were classified in active samples
(symbol A, if IC50< 40 μl/mL), or inactive extracts (symbol I, if
IC50> 40 μl/mL) (Table 1).
PCA based on 1H-NMR, was carried out for the most significant
variables, those able to discriminate active and inactive honeys (stan-
dard deviation> 20 and CV%>80) (Fig. 4A). PCA highlighted a good
separation of the two groups; in particular, LDA calculated on the three
principal components showed that only 10.1% of objects resulted
wrongly classified. Frequencies between 1.5 and 3.0 ppm and between
8.0 and 8.5 ppm, strongly affected the first main component (52.8% of
the total variance); as consequence, they better explained the differ-
ences between the two groups of samples.
It is noteworthy that the sum of peak heights in the frequency range
between 1.80–1.90 ppm (Σh), was strongly related with IC50 values (r
= −0.79, Fig. 4B), so indicating that the active molecule(s) has/have
protons that resonates in that spectral range.
PCA analysis from HPLC was carried out for the most significant
variables, that were those able to discriminate active and inactive
honeys (standard deviation>20, CV%>80 and area> 100; Fig. 4C).
The best results by PCA, in terms of separation between the two groups,
were obtained with the area values at 280 nm. LDA calculated on three
main components showed that only 10.1% of objects resulted wrongly
classified. Finally, a third PCA was generated by using both the vari-
ables obtained from 1H-NMR and HPLC (Fig. 4D). Following this latter
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approach the number of objects wrongly classified diminished until
5.6%.
The next step was the chemical characterization of the active honey.
To this aim, the different variables (range of resonance frequencies and
range of retention times) were correlated by using a correlation matrix,
as reported in Table 3. The matrix shows a first correlation between
HPLC-peaks with retention times in the range of 7.0–8.0 min, and with
1H-NMR signals in four of the five evaluated ranges of ppm (1.5–2.0;
Fig. 1. Evaluation of the inhibitory power of honey extracts. Preliminary screening was carried out by using a fixed amount of each extracts (10 μL/mL), an
aliquot of recombinant PTP1B enzyme (5 μL), and p-NPP as substrate (2.5 mM final concentration). Data obtained were normalized respect to the control sample.
Data reported in the figure represent the mean value +/- S.E.M. (n=3) (* p < 0.05). (A), honeydew; (B), chestnut; (C), wildflowers; (D), acacia. (E), average
reduction +/- S.E.M. of PTP1B activity (n=5); (F), coefficient of determination. The IC50 values were plotted versus the total content of polyphenols (full square)
and flavonoids (empty circles). The IC50 values obtained from acacia extracts were not included in this analysis.
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2.0–2.5; 2.5–3.0 and 8.0–8.5 ppm). A second correlation was between
HPLC-peaks with retention times of 4.0–5.0min, and with 1H-NMR
signals in three ranges of ppm (1.5–2.0; 2.0–2.5; and 2.5–3.0 ppm). In
light of these results, we can predict a honey as active in inhibition of
PTP1B when 1H-NMR spectra shown signals at 1.5–3.0 and 8.0–8.5 ppm
correlated with HPLC-peaks detected at 280 nm, with retention times in
the range of 7.0–8.0min.
3.6. LC–MS analysis
To identify the compounds responsible for PTP1B inhibition, LC–MS
analysis was carried out by using aliquots of H4, C2, and W4 honey
extracts, recognized as the most active samples. By comparing the data
obtained with those of a library of compounds detected in honey
[18–21] (Supplementary material, Table 4), we have identified dif-
ferent masses that can be related to the compounds shown in Table 5.
Some of these such as kurarinone [22], acacetin, chrysin [23], pino-
cembrin [24], naringenin [25], apigenin [26], and caffeic acid, [27]
were previously recognized as PTP1B inhibitors. Other compounds,
such as Kushenol A and Kushenol K, are structurally similar to la-
vandulyl flavonoids, which are potent PTP1B inhibitors, suggesting that
even these molecules could contribute to the inhibitory power of these
honey extracts [17,18]. Finally, we found that fisetin and eriodictyol,
flavonoids detected in H4 and W4 samples, behaved as potent PTP1B
inhibitors, showing an IC50 value of 0.6±0.01, and 33.4±1.8 μM,
respectively (Supplementary Fig. 10). Taken together, these results
demonstrated that honey extracts contain different natural PTP1B in-
hibitors.
Table 1
IC50 values, and classification of honey samples. The IC50 values were de-
termined using PTP1B enzyme (for more details, see materials and method
section). Classification of honey samples was carried out setting the cutoff at 40
μL/mL. “A” indicates active honey samples, whereas “I” indicates inactive
honey samples.
Honey extracts IC50
(μL/mL))
Classification*
Honeydew
H1 33.7 ± 1.5 A
H2 5.8 ± 0.3 A
H3 11.3 ± 0.4 A
H4 3.1 ± 0.3 A
H5 6.5 ± 0.3 A
Wildflowers
W1 17.9 ± 2.3 A
W2 44.9 ± 2.8 I
W3 43.6 ± 1.8 I
W4 10.3 ± 1.1 A
W5 42.0 ± 2.9 I
Chestnut
C1 35.3 ± 4.2 A
C2 18.0 ± 0.8 A
C3 30.7 ± 1.4 A
C4 12.2 ± 0.8 A
C5 42.8 ± 5.0 I
Acacia
A1 >50 I
A2 >50 I
A3 >50 I
A4 >50 I
A5 >50 I
* A=Active; I= Inactive.
Fig. 2. Double reciprocal plots obtained by using PTP1B and active honey
extracts. All data reported in the figures represent the mean values± S.E.M.
(n= 3). Experimental points were fitted by using Microcal Origin softer pro-
gram (OriginLab Corporation, Northampton, Massachusetts, USA.). (A), hon-
eydew extract (H4). ■, control; ○, 1 μL/mL; ▲, 2 μL/mL; ▽, 4 μL/mL. (B),
wildflowers extract (W4). ■, control; ○, 5 μL/mL; ▲, 10 μL/mL ; ▽, 20 μL/
mL. (C), chestnut extracts (C2). ■, control; ○, 5 μL/mL;▲, 10 μL/mL;▽, 20
μL/mL.
Table 2
Ki values and action mechanism of honey extracts.
Honey extract Inhibition type Ki (μL/mL) α
H4 Linear Mixed type 0.8 ± 0.07 1.3 ± 0.1
W4 Linear Mixed type 6.8 ± 0.2 10.8 ± 2.5
C2 Linear Mixed type 24.7 ± 1.0 2.4 ± 0.3
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3.7. Ex vivo assays
We used HepG2 cells to assess the effects of honey extracts on liver
cells. Preliminary tests carry out with liver cells treated with honey
extracts alone showed that these were not able to enhance phosphor-
ylation levels of insulin receptor, neither after 5 days chronic stimula-
tion. This finding suggest that honey extracts do not possess insulin
mimetic activity. On the other hand, we know that honey, because of its
elevate content in glucose, stimulates the release of insulin [8]. Based
on these evidences, we decided to study the effects of honey extracts in
co-stimulation with insulin, to evaluate whether the extracts possess
insulin-sensitizing activity. Cells were grown in starvation medium for
96 h, in presence or not of H4 honey extract, and then were stimulated
with insulin. Phosphorylation levels, as well as total IR expression levels
were evaluated by immunoblot. We found that cells treated with honey
extracts expressed higher IR levels respect to control cells, improving
insulin-signalling transduction, through higher IR phosphorylation le-
vels (Fig. 5). Interestingly, we observed that all the extracts were active
in stimulating IR expression in HepG2 cells, even if H4 and W4 samples
resulted more active than C2 and A5 extracts (Fig. 6A, B).
Then, to evaluate whether treatment with honey extracts was able
to boost insulin signalling, we measured the rate of glucose in-
corporation in liver cells treated with the honey extracts and stimulated
with insulin. We found that glucose incorporation was higher in liver
cells pre-treated with C2, W4 and H4 honey extracts than in control
cells (Fig. 7). On the contrary, no significant increase of glucose uptake
was observed in liver cells treated with the A5 extract respect to control
cells. Taken together, these results showed that treatment with honey
extracts stimulated IR expression, increased IR phosphorylation levels,
and, in some cases, enhanced glucose uptake in liver cells. We suggest
that the inactivity of acacia extract (A5) in enhancing glucose uptake
could be due to low content of bioactive molecules in this type of
honey.
4. Discussion
Honey is a natural food, which possesses medical properties such as
antioxidant, anti-inflammatory, antibacterial, antiviral and antitumoral
activities [28]. Preclinical and clinical studies conducted in the last
decades, demonstrated also that the regular assumption of honey im-
proves glycaemic control in mice and humans affected by diabetes,
reduces levels of glycosylated haemoglobin, and favours the loss of
body weight [10,29,30]. However, to date the molecular bases of the
anti-diabetic activity of honey remain to be clarified.
We focused our study on evaluating the effect of honey on PTP1B,
one the most interesting targets for treatment of type II diabetes and
obesity [31]. Aim of this study was to evaluate i) whether natural
compounds present in this food are able to inhibit this enzyme, and ii)
whether honey could have a positive impact on insulin signaling
pathway. Moreover, to eliminate confounding elements, we decided to
analyze the effects of hydroalcoholic extracts instead of whole honey,
and to treat liver cells with small amount of these extracts, thereby
simulating the effect of a moderate daily assumption. This experimental
approach is different from that used in most of studies conducted on
honey to date, which, conversely, evaluated the effects of acute ad-
ministration of relevant amount of honey [32–34]. Although the use of
such an experimental approach would have favoured the achievement
of a positive outcome also in our studies, we have excluded it since it
would have been impracticable with humans. In fact, is important to
remember that honey is rich in glucose, and that chronic assumption of
high amount of this food could lead severe side effects both in healthy
than in diabetic subjects. Finally, we analyzed the effects of extracts
only in co-stimulation with insulin, confident that in humans the nat-
ural compounds and insulin cannot act independently after honey as-
sumption.
We showed that honey extracts are able to inhibit PTP1B in vitro,
being the inhibitory power strictly related to the content of natural
compounds. Mass spectrometry analyses revealed that honey extracts
Fig. 3. Evaluation of the inhibitory power of honey fractions eluted from
semipreparative HPLC. One hundred microliters of H4, C2, and W4 honey
extracts were injected in into C18 column (Kinetex 5 μm C18 100 Å LC Column
250×4.6mm). Elution solvent was collected in 4 fractions: Fraction 1:
9–11min; Fraction 2: 15–22min; Fraction 3: 24–28.5min; Fraction 4:
30–40min. Fraction were drying under vacuum. Then, the dry residue was
solubilized in 100 μL of 80% ethanol solution. Inhibitory power of these solu-
tions was evaluated by enzymatic assay, mixing 10 μL of solution into 1mL of
buffer assay containing substrate of PTP1B enzyme. (A) was for H4 honey ex-
tract; (B) was for C2 honey extract and (C) was for the W4 honey extract, re-
spectively. (* p < 0.05).
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Fig. 4. PCA and LDA data. (A), biplot diagram of PCA obtained from 1H-NMR data. The original variables are indicated with vectors at the end of which the starting
range values are shown (e.g. variable “2″ is the frequency range 2.0–2.5 ppm). Letters and numbers identified each sample. (B), IC50 values vs sum of peak height
frequencies range 1.80–1.90 ppm (Σh). (C), biplot diagram of PCA obtained from HPLC data. The original variables are indicated with vectors at the end of which the
starting range values are shown (e.g. variable “4″ is the range of retentions times 4.0–5.0min). (D), score plot diagram of PCA obtained from 1H-NMR and HPLC data.
Table 3
Correlation matrix (range of resonance frequencies vs range of retention times). The table highlights the HPLC peaks that correlate, with a significant
correlation coefficient, with the greatest number of 1H-NMR signals.
1.0-1.5 ppm 1.5-2.0 ppm 2.0-2.5 ppm 2.5-3.0 ppm 8.0-8.5 ppm
4-5min 0.14 0.75 0.62 0.75 0.36
5-6min 0.26 0.21 0.26 0.48 0.01
6-7 min 0.12 0.54 0.40 0.44 −0.02
7-8min 0.11 0.72 0.65 0.70 0.70
8-9 min −0.12 −0.07 −0.10 −0.03 −0.62
9-10min −0.22 −0.26 −0.28 −0.30 −0.42
13-14 min −0.01 0.20 0.19 0.07 0.77
14-15min 0.69 −0.01 0.34 −0.05 −0.10
15-16min 0.68 0.08 0.41 0.02 0.04
16-17 min 0.69 0.16 0.42 0.11 0.01
17-18min 0.71 −0.04 0.34 −0.05 −0.19
18-19 min 0.68 −0.08 0.32 −0.08 −0.21
19-20min 0.65 −0.06 0.32 −0.08 −0.08
22-23 min 0.68 −0.03 0.35 −0.06 −0.07
36-37min 0.01 0.46 0.30 0.31 0.05
G. Lori, et al. Biomedicine & Pharmacotherapy 113 (2019) 108752
8
contained small lipophilic molecules containing phenolic groups and
aliphatic substituents. It is interesting to underline that several com-
pounds bearing these physical-chemical properties have been already
classified as PTP1B inhibitors [15]. Moreover, in vivo experiments
showed that chronic stimulation with extracts enhanced expression and
phosphorylation levels of insulin receptor, and stimulated glucose ab-
sorption. Even if the increase of IR phosphorylation is an expected re-
sult, as consequence of the PTP1B inhibition, conversely, the increase of
insulin-receptor expression levels is a particular interesting result that
could open new scenarios in studying the roles of nutraceuticals in
insulin signalling. To date, we do not know the mechanisms by which
honey extracts regulate the expression of the insulin receptor. We can
speculate that some of the extract components could activate specific
transcription factors, or could inhibit β-site amyloid precursor protein
cleaving enzyme 1 (BACE1) which, cleaving insulin receptor ectodo-
main, regulates insulin signaling in the liver [35]. Together, data re-
ported in this study reinforce the hypothesis that honey can acts as
antihyperglicaemic food, regulating the expression of insulin receptor
and enhancing insulin sensitivity.
Table 4
Library of compounds detected in honey. Data reported in the table were ob-
tained from published papers [18–21].
Monoisotopic mass Molecular
Formula
Name of compound
196.0736 C10H12O4 4-methoxyphenyllactic acid
120.05751 C8H8O Methylated Luteolin
122.03678 C7H6O2 Benzoic Acid
126.03169 C6H6O3 Hydroxymethylfurfural
136.05243 C8H8O2 Phenylacetic acid
138.03169 C7H6O3 3-hydroxybenzoic acid
138.03169 C7H6O3 4-hydroxybenzoic acid
138.03169 C7H6O3 p-Hydroxybenzoic Acid
138.03169 C7H6O3 Salicylic acid
142.02661 C6H6O4 Kojic acid
148.05243 C9H8O2 Cinnamic Acid
148.05243 C9H8O2 Thymol
148.05243 C9H8O2 Trans-cinnamic acid
150.10446 C10H14O Carvacrol
152.04730 C8H8O3 Mandelic acid
152.04734 C8H8O3 2-methoxybenzoic acid
152.04734 C8H8O3 4-hydroxyphenyl acetic acid
152.04734 C8H8O3 4-methoxybenzoic acid
152.04734 C8H8O3 p-hydroxyphenylacetic acid
154.02661 C7H6O4 2,4-Dihydroxybenzoic Acid
154.02661 C7H6O4 Gentisic acid
154.02661 C7H6O4 Protocatechuic acid
164.04734 C9H8O3 m-Coumaric Acid
164.04734 C9H8O3 o-Coumaric Acid
164.04734 C9H8O3 p-Coumaric acid
164.04734 C9H8O3 p-hydroxycinnamic acid
165.07897 C9H11NO2 Phenylalanine
166.06299 C9H10O3 L-(-)-phenyllactic acid
168.04226 C8H8O4 4-hydroxy-3-methoxybenzoic acid
168.04226 C8H8O4 Homogentisic acid
168.04226 C8H8O4 Vanillic Acid
170.02152 C7H6O5 Gallic acid
180.04226 C9H8O4 Caffeic Acid
182.05791 C9H10O4 DL-p-hydroxy-phenyllactic acid
189.04259 C10H7NO3 Kynurenic acid
194.05791 C10H10O4 Coniferic acid
194.05791 C10H10O4 Ferulic acid
198.05282 C9H10O5 Syringic acid
212.06847 C10H12O5 Methyl Syringate
222.08921 C12H14O4 3-hydroxy-1-(2-methoxyphenyl)penta-
1,4-dione
222.12559 C13H18O Dehydrovomifoliol
224.06847 C11H12O5 Sinapic acid
228.07864 C14H12O3 Resveratrol
242.08037 C12H10N4O2 Lumichrome
248.10486 C14H16O4 Dimethylallylcaffeate
254.05791 C15H10O4 Chrysin
256.07356 C15H12O4 Pinocembrin
264.13616 C15H20O4 Abscisic acid
264.13616 C15H20O4 Trans–trans abscisic acid
264.13616 C15H20O4 Trans–Trans-Abscisic Acid
268.07356 C16H12O4 Tecthochrysin
270.05282 C15H10O5 Apigenin
270.05282 C15H10O5 Baicalein
270.05282 C15H10O5 Galangin
270.05282 C15H10O5 Genistein
270.08921 C16H14O4 Pinocembrin 7-Methylether
272.06847 C15H12O5 Naringenin
272.06847 C15H12O5 Pinobankisin
284.06847 C16H12O5 Acacetin
284.06847 C16H12O5 Galangin 3-Methyl Ether
284.06847 C16H12O5 Genkwanin
284.10486 C17H16O4 Phenylethyl Caffeate
286.04774 C15H10O6 Fisetin
286.04774 C15H10O6 Luteolin
286.08412 C16H14O5 Pinobanksin methyl ether
288.06339 C15H12O6 Eriodictyol
290.07904 C15H14O6 Catechin
290.07904 C15H14O6 Epicatechin
300.06339 C16H12O6 Kaempferid
300.06339 C16H12O6 Kaempferol 8-Methyl Ether
300.06339 C16H12O6 Methylbenzaldehyde
Table 4 (continued)
Monoisotopic mass Molecular
Formula
Name of compound
302.00627 C14H6O8 Ellagic Acid
302.04265 C15H10O7 Tricetin
302.07904 C16H14O6 Hesperetin
306.07395 C15H14O Epigallocatechin
306.07395 C15H14O7 Gallocatechin
314.07904 C17H14O6 Pinobanksin acetate
316.05830 C16H12O7 3-Methylquercetin
316.05830 C16H12O7 8-Methoxy Kaempferol
316.05830 C16H12O7 Isorhamnetin
316.05830 C16H12O7 Quercetin-3-methyl ether
318.03757 C15H10O8 Myricetin
330.07395 C17H14O7 Quercetin 3,3-Dimethyl Ether"
330.07395 C17H14O7 Quercetin 3,7-dimethyl ether"
330.07395 C17H14O7 Quercetin 7,3’-dimethyl ether"
330.07395 C17H14O7 Quercetin-3,3’-dimethyl ether
342.11034 C19H18O6 Pinobanksin butyrate
354.09508 C16H18O9 caffeoylquinic acid
354.09508 C16H18O9 Chlorogenic acid
354.14672 C21H22O5 Isoxanthohumol
360.08452 C18H16O8 Rosmarinic Acid
370.14164 C21H22O6 (2R)-3,7,4'-trihydroxy-5-methoxy-8-
dimethylallyl flavanone
376.13828 C17H20N4O6 Riboflavin
408.19367 C25H28O5 Andkushenol A
424.18859 C25H28O6 Sophora-flavanone G
438.16785 C25H26O7 Kushenol C
438.20424 C26H30O Kuraridine
438.20424 C26H30O6 kurarinone
438.20424 C26H30O6 Leachianone A
447.09274 C21H19O11 8-Methoxy kaempferol Glycoside
448.10056 C21H20O11 Kaempferol Glycoside
448.10056 C21H20O11 Luteolin Glycoside
448.10056 C21H20O11 Quercetin
454.19915 C26H30O7 Askushenol H
454.19915 C26H30O7 Kushenol N
456.21480 C26H32O7 Kurarinol
458.08491 C22H18O11 Epigallocatechin gallate
458.08491 C22H18O11 Gallocatechin gallate
464.09548 C21H20O12 Quercetin Glycoside
470.23045 C27H34O7 Neokurarinol
472.20972 C26H32O8 Kushenol K
494.10604 C22H22O13 Myricetin 3,7,4,5-Methyl Ether
580.17921 C27H32O14 Naringin
594.15847 C27H30O15 Kaempferol rutinoside
610.15339 C27H30O16 Quercetin rutinoside
610.15339 C27H30O16 Quercetin-3-o-rutinoside
610.15339 C27H30O16 Rutin
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Despite these results appeared interesting, their relevance in hu-
mans remain to be established. For a long time, medicinal plants with
antidiabetic potential were the only resource for treating diabetes in
humans. In the last decades, several scientific studies have highlighted
the molecular basis of antidiabetic activity of medicinal plants, con-
firming that these contain a large number of natural compounds. To
date, we know that most of those have a positive impact in regulating
glycaemia in diabetic mouse models, inhibiting glucose absorption in
the gut, acting as insulin-mimetic or insulin-sensitizing agents [14],
protecting pancreatic beta cells from apoptosis, or to stimulating insulin
secretion [36,37]. Taking into account the effects of honey, studies
conducted in the last decades both in vitro and in vivo have generated
contrasting results [4]. The reasons are imputable to different kind of
experimental protocols used, the kind of honey, the doses administered,
and, most probably, to the tentative of evaluate the acute effect of
honey. We think that, before to address this kind of studies, some im-
portant considerations must be made. First, honey is a food rich in
glucose, which excluded the possibility to be administered in high doses
to diabetic patients, without the risk to induce severe side effects (i.e.
the gradual increase of HbA1c). Latter, there is a limit in the intestinal
absorption of most of bioactive constituents, suggesting that the chronic
administration of small doses could be more effective and safe proce-
dure than the administration of a relevant amount in a single dose.
Unfortunately, in the last decades only two studies has been conducted
to evaluate the effects of chronic assumption of honey on diabetic
people [10,34]. Nevertheless, it is interesting to highlight that the study
conducted by Abdulrhman MM and colleagues, reports that the ad-
ministration of honey (0.5mL/Kg) for 12 weeks resulted in significant
decreases in fasting serum glucose, and significant increases in both
fasting and 2-h postprandial C-peptide levels. More interestingly, pa-
tients affected by type 1 diabetes, also after honey withdrawal, main-
tained reduction in fasting serum glucose, 2-h postprandial serum
glucose, and HbA1C levels. These findings reinforced the hypothesis that
long-term consumption of honey might have positive effects on gly-
caemic control in these patients.
Further analyses are necessary to evaluate levels of bioactive com-
pounds absorbed by gut of humans depending on the dose of honey
assumed, and their effect on different organs such as liver, muscle and
adipose tissue.
5. Conclusions
In summary, the results of this study demonstrate for the first time
that honey contains bioactive molecules able to improve insulin sig-
naling. Our results clearly show that several honey extracts are able to
inhibit PTP1B enzyme, and upregulate IR expression, thereby in-
creasing insulin sensitivity. We believe these effects can have relevant
clinical significance if confirmed also in humans. Indeed, down-
regulation of insulin receptor has been observed in hepatocytes
chronically stimulated with insulin. The reduction of IR expression
causes, in turn, the attenuation of insulin signaling pathway, which
results in the constitutive activation of gluconeogenesis [38]. In light of
the results of this study, we speculate that regular assumption of certain
type of honey, by providing bioactive molecules able to simulate IR
expression and inhibit PTP1B, could contributes to interrupt this vi-
cious circle, thereby helping in restoring the correct insulin function.
Furthermore, it is important to underline that the enhancement of in-
sulin expression was achieved through a chronic stimulation of liver
Table 5
List of masses detected in honey extracts. Molecular weight of compounds present in honey extracts were determined by using a HPLC-MS apparatus. The
identification of compounds was carried out by comparing the experimental findings with data reported in the Table 4.
Compounds rt (min) M.W. Measured
M.W.
Modality H4 C2 W4 Ref.
Kushenol A 38.46 408.494 407,1875 neg – ✓ ✓
Kurarinone, or
Kuraridine, or
Leachianone A
36.21 438.20 437,1925 neg ✓ ✓ ✓ [18]
Acacetin, or
Galangin 3-Methyl Ether, or
Genkwanin
35.96 284.07 283,0625 neg ✓ ✓ ✓ [19]
Pinobanksin methyl ether 35.96 286.27 285,0775 neg ✓ ✓ ✓
Apigenin, or
Baicalein, or
Galangin, or
Genistein
35.71 270.052 269,0475 neg ✓ ✓ ✓ [19,22]
Chrysin 35.46 254.058 253,0525 neg ✓ ✓ ✓ [19]
Phenylethyl Caffeate 35.46 284.311 283,097 neg ✓ ✓
Pinocembrin 34.71 256.257 255,06 neg ✓ ✓ ✓ [20]
Quercetin 3,4'-dimethyl ether 34.21 330.074 331,082 pos ✓ ✓ ✓
Dimethylallyl
Caffeate
33.96 248.27 247,0975 neg – ✓ –
Tectochrysin 32.46 268.073 267,0675 neg ✓ – ✓
Fisetin, or kaempferol, or
luteolin
31.71 286.04 285,0425 neg ✓ – ✓ [19]
Eriodictyol 31.71 288,063 287,0525 neg ✓ – ✓
Naringenin, or
Pinobankisin
29.21 272.06 273,0775 pos ✓ ✓ ✓ [21]
Abscisic acid 25.21 264.13 263,1275 neg ✓ ✓ ✓
Kushenol K 24.71 472.21 473,2175 pos – – ✓
Kaempferol rutinoside 22.71 594.15 593,1525 neg – – ✓
Coniferic acid 19.96 194.057 195,0675 pos ✓ – ✓
Hesperetin 18.71 302.079 303,0825 pos – – ✓
4-methoxy-phenylactic acid 16.71 166.062 165,0525 neg – – ✓
Caffeic acid 10.96 180.04 179,0325 neg ✓ ✓ ✓ [23]
Kynurenic acid 8.46 189.04 190,0475 pos ✓ ✓ ✓
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cells with very low amount of honey extracts, a condition that would
mimicking a dietary regimen that includes daily assumption of mod-
erate amount of honey.
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Fig. 5. Effects of honeydew extract (H4) on insulin receptor activation.
HepG2 cells were treated with H4 honey extract (final concentration of extract
was indicated in the figure) for 96 h and then stimulated with insulin.
Phosphorylation levels, and total amount of insulin receptor, were evaluated by
immunoblot, using specific antibodies. Quantification of immunoblot bands
was carried out using Kodak MI software. Data obtained were normalized re-
spect to control samples. Beta-actin was used as a loading control. Data reported
in the figures, represent the mean values± S.E.M. (n= 3) (* p < 0.05).
Western blot (top). Quantification of phosphorylation levels of IR (middle).
Quantification of expression levels of IR (bottom).
Fig. 6. Expression levels of insulin receptor in HepG2 cells treated with
honey extracts. HepG2 cells were incubated with selected honey extracts for
96 h. Final concentration of honey extracts in each samples was 0.02%. After
96 h, total amount of insulin receptor was determined by immunoblot, using
specific antibodies. The quantification of samples (B) was carried out using
Kodak MI program. Beta-actin was used as a loading control. Data reported in
the figure, represent the mean values± S.E.M. (n=3) *p < 0.01; #
p < 0.05.
Fig. 7. Glucose uptake in HepG2 cells. Liver cells were treated for 4 days with
honey extracts (0.02% final concentration). Every day, mediun was withdrawn
and substituted with fresh medium containing fresh honey extracts. After four
days, cells were washed with PBS and then incubated in the presence of [3H]-
deoxy-D-Glucose (0.5 μCi/mL final concentration) for 15min. After, the cells
were washed twice with ice-cold phosphate-buffered saline, and lysed using
500 μL of 0.1M NaOH solution and assayed to determine the amount of [3H]-
deoxy-D-Glucose incorporated using a liquid scintillation analyzer (Tri-Carb
2800TR, PerkinElmer). Data were normalized respect to protein content. All
data were normalized respect to control samples. Data reported in the figure
represent the mean value± S.E.M. *p < 0.05 (n= 4).
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